Overall, it appears that establishing α-synuclein as a good biomarker for PD will require well-validated detection methods and larger clinical studies (cross-sectional and follow-up) with PD patients, patients of parkinsonian disorders, and non-parkinsonian movement disorders. Here, SNCA is linked to parkinsonian disorder.